Literature DB >> 28512056

Combined proportional and additive residual error models in population pharmacokinetic modelling.

Johannes H Proost1.   

Abstract

INTRODUCTION: In pharmacokinetic modelling, a combined proportional and additive residual error model is often preferred over a proportional or additive residual error model. Different approaches have been proposed, but a comparison between approaches is still lacking.
METHODS: The theoretical background of the methods is described. Method VAR assumes that the variance of the residual error is the sum of the statistically independent proportional and additive components; this method can be coded in three ways. Method SD assumes that the standard deviation of the residual error is the sum of the proportional and additive components. Using datasets from literature and simulations based on these datasets, the methods are compared using NONMEM.
RESULTS: The different coding of methods VAR yield identical results. Using method SD, the values of the parameters describing residual error are lower than for method VAR, but the values of the structural parameters and their inter-individual variability are hardly affected by the choice of the method.
CONCLUSION: Both methods are valid approaches in combined proportional and additive residual error modelling, and selection may be based on OFV. When the result of an analysis is used for simulation purposes, it is essential that the simulation tool uses the same method as used during analysis.
Copyright © 2017 Elsevier B.V. All rights reserved.

Keywords:  Combined residual error; Pharmacokinetic modelling; Residual error modelling

Mesh:

Substances:

Year:  2017        PMID: 28512056     DOI: 10.1016/j.ejps.2017.05.021

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  5 in total

1.  Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib.

Authors:  Ki Young Huh; Sejung Hwang; Sang Yeob Park; Hye Jung Lim; Miryung Jin; Jaeseong Oh; Kyung Sang Yu; Jae Yong Chung
Journal:  Pharmaceutics       Date:  2021-04-28       Impact factor: 6.321

2.  Model-Based Equivalent Dose Optimization to Develop New Donepezil Patch Formulation.

Authors:  Woojin Jung; Heeyoon Jung; Ngoc-Anh Thi Vu; Gwan-Young Kim; Gyoung-Won Kim; Jung-Woo Chae; Taeheon Kim; Hwi-Yeol Yun
Journal:  Pharmaceutics       Date:  2022-01-20       Impact factor: 6.321

3.  Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg.

Authors:  Yi-Han Chien; Gudrun Würthwein; Pablo Zubiaur; Bianca Posocco; María Ángeles Pena; Alberto M Borobia; Sara Gagno; Francisco Abad-Santos; Georg Hempel
Journal:  Cancer Chemother Pharmacol       Date:  2022-07-14       Impact factor: 3.288

4.  Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney Disease.

Authors:  Hiroyuki Takita; Daniel Scotcher; Xiaoyan Chu; Ka Lai Yee; Kayode Ogungbenro; Aleksandra Galetin
Journal:  Clin Pharmacol Ther       Date:  2022-06-28       Impact factor: 6.903

5.  Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients.

Authors:  Tim Preijers; Ri Liesner; Hendrika C A M Hazendonk; Pratima Chowdary; Mariëtte H E Driessens; Dan P Hart; Britta A P Laros-van Gorkom; Felix J M van der Meer; Karina Meijer; Karin Fijnvandraat; Frank W G Leebeek; Ron A A Mathôt; Marjon H Cnossen
Journal:  Br J Clin Pharmacol       Date:  2021-05-04       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.